Understanding Tavapadon’s Mechanism and Clinical Potential in Treating Parkinson Disease: Hubert Fernandez, MD

WATCH TIME: 4 minutes

“What makes tavapadon unique is its D1 selectivity. We can stimulate motor pathways effectively, but the hope is to avoid the baggage that comes with D2 stimulation, particularly the nonmotor side effects.”

Treatment of Parkinson disease (PD) has long centered on dopaminergic therapies aimed at improving motor symptoms, most notably levodopa and dopamine agonists. While effective, these treatments are often limited by dosing complexity and the risk of adverse effects, particularly with nonselective dopamine receptor stimulation. As a result, there remains a need for therapies that can provide consistent symptomatic benefit with improved tolerability and ease of use across different stages of disease.

Tavapadon (AbbVie) is an investigational, once-daily dopamine agonist that selectively targets the D1 receptor family, a mechanism designed to more specifically modulate motor pathways. Unlike traditional dopamine agonists, which often stimulate both D1- and D2-like receptors, tavapadon’s selectivity aims to preserve efficacy while potentially reducing nonmotor adverse effects such as hallucinations, impulse control disorders, and orthostatic hypotension.

Following the 2026 American Academy of Neurology (AAN) Annual Meeting, Hubert Fernandez, MD, director of the Center for Neurological Restoration at Cleveland Clinic, discussed the clinical development of tavapadon, including findings from the phase 3 TEMPO-4 extension study. Currently, tavapadon remains under review by the FDA, with a decision expected to come in the first half of 2026.

In a conversation with NeurologyLive®, Fernandez outlined the mechanism and rationale behind tavapadon, highlighting its D1 selectivity, extended half-life, and once-daily dosing profile. He also discusses how these features may translate into improved tolerability, adherence, and patient satisfaction, as well as the potential role of the therapy across different stages of PD if approved.

Click here for more AAN 2026 coverage.

REFERENCE
1. Ondo W, Hatcher M, Soileau M, et al. Levodopa initiation or dose adjustments in TEMPO-4: a 58-week open-label trial of tavapadon for treatment of Parkinson disease. Presented at: 2026 American Academy of Neurology Annual Meeting; April 18-22, 2026; Chicago, Illionis